Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + Bendamustine + Rituximab in R/R NHL
NCT02187133Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- May 2015
- Primary completion
- Mar 2021
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib in B-cell non-Hodgkin lymphoma, sponsored by University of California, San Francisco. Primary endpoints: Maximally Tolerated Dose at 28 days and Dose Limiting Toxicities at 28 days. Started May 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02187133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187133.